Table 3.

Prevalence of ASIL endpoints and the prevalence of HPV DNA within ASIL endpoints in the baseline visit in 605 men with complete baseline results on cytology, histology, and HPV in the Study of the Prevention of Anal Cancer

Prevalence of HPV by ASIL endpoint
Number and proportion in each groupHPV16All other HR-HPV typesLR-HPV only
Disease categoryDefinitionN% (95% CI)n (%)n (%)n (%)
Composite-negativeVisually normal HRA with no biopsy taken, or no evidence of ASIL on any biopsy, and normal or unsatisfactory cytology18129.9 (26.3–33.7)22 (12.1)50 (27.6)54 (29.8)
Composite-LSILLSIL or ASCUS cytology and/or LSIL histology as the highest grade of ASIL15125.0 (21.6–28.6)28 (18.5)59 (39.1)47 (31.1)
Composite-ASC-HASC-H cytology and no HSIL (≤LSIL) on histology457.4 (5.5–9.8)14 (31.1)19 (42.2)10 (22.2)
Composite-HSILHSIL detected by either cytology or histology22837.7 (33.8–41.7)114 (50.0)89 (39.0)19 (8.3)
 HSIL-AIN2HSIL-AIN2 on cytology and/or AIN2 on histology without a diagnosis of AIN3 on either518.4 (6.3–10.9)11 (21.6)31 (60.8)7 (13.7)
 HSIL-AIN3HSIL-AIN3 on cytology or histology17729.3 (25.6–33.1)103 (58.2)58 (32.8)12 (6.8)
HSIL cytology regardless of histology results10817.9 (14.9–21.1)64 (59.3)34 (31.5)6 (5.6)
HSIL histology regardless of cytology results19231.7 (28.0–35.6)98 (51.0)74 (38.5)15 (7.8)
  • Abbreviation: AIN, anal intraepithelial neoplasia.